| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.0081 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |